No Negative in Madrigal Pharma's (MDGL) Topline Data Delay - H. C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to No Negative in Madrigal Pharma's (MDGL) Topline Data Delay - H. C. Wainwright
December 30, 2021 9:29 AM EST
Pre-Open Stock Movers:
Biogen (NASDAQ: BIIB) 5.5% LOWER; Samsung Group denied it is engaged in talks to acquire the biotech firm.
Naked Brand Group Limited (NASDAQ: NAKD) 4.7% HIGHER; sees continued momentum.
DiDi Global Inc. (NYSE:... More
December 30, 2021 8:01 AM EST
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with non-alcoholic fatty liver disease, presumed NASH.
Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, Although the blinded study data were delivered to the vendor conducting the statistical analyses on time, unexpected staffing issues at the vendor delayed their analyses of the initial MRI-PDFF and lipid data planned for release by year end. We now expect to announce topline 52-week results from the study in January... More
